PMID: 8592651Sep 29, 1995Paper

Differential blockade of morphine and morphine-6 beta-glucuronide analgesia by antisense oligodeoxynucleotides directed against MOR-1 and G-protein alpha subunits in rats

Neuroscience Letters
G C RossiG W Pasternak

Abstract

An antisense oligodeoxynucleotide directed against the 5'-untranslated region of MOR-1 blocks the analgesic actions of the mu 1 analgesics morphine and [D-Ala2,D-Leu5]enkephalin (DADL) when they are microinjected into the periaqueductal gray. In contrast, morphine-6 beta-glucuronide (M6G) analgesia is unaffected by this treatment. Antisense oligodeoxynucleotides directed against distinct Gi alpha subunits also distinguish between morphine and M6G analgesia. A probe targeting Gi alpha 2 blocks morphine analgesia, as previously reported, but is inactive against M6G analgesia. Conversely, an antisense oligodeoxynucleotide against Gi alpha 1 inhibits M6G analgesia without affecting morphine analgesia. The antisense oligodeoxynucleotide directed against G(o)alpha is ineffective against both compounds. These results confirm the prior association of Gi alpha 2 with morphine analgesia and strongly suggests that M6G acts through a different opioid receptor, as revealed by its insensitivity towards the MOR-1 antisense probe and differential sensitivity towards G-protein alpha subunit antisense oligodeoxynucleotides.

References

Dec 28, 1987·Life Sciences·G W PasternakC E Inturrisi
Dec 1, 1993·Trends in Neurosciences·T Reisine, G I Bell
Mar 1, 1994·Trends in Neurosciences·G R UhlG Pasternak
Jun 2, 1994·European Journal of Pharmacology·R B RaffaC D Connelly
Sep 13, 1994·Proceedings of the National Academy of Sciences of the United States of America·B H MinH H Loh
Feb 1, 1993·Clinical Neuropharmacology·G W Pasternak
Nov 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·J B WangG R Uhl
Oct 8, 1993·Brain Research·G C RossiR J Bodnar

❮ Previous
Next ❯

Citations

Sep 20, 1996·Neuroscience Letters·G C RossiG W Pasternak
May 24, 2005·Journal of Pain and Symptom Management·Gavril W Pasternak
Mar 17, 1999·Biochemical Pharmacology·M KingG W Pasternak
Aug 1, 1998·European Journal of Pharmacology·A ChangG W Pasternak
Jun 6, 2000·Pharmacology, Biochemistry, and Behavior·M GrungJ Mørland
Mar 20, 2002·Pharmacology, Biochemistry, and Behavior·Benedict A GomesByron C Yoburn
May 10, 2003·Brain Research. Brain Research Reviews·Dirk Van OekelenJosée E Leysen
May 1, 1997·Cellular Signalling·K M Standifer, G W Pasternak
Feb 13, 2002·Drug Discovery Today·Alan WiseStephen Rees
May 27, 2011·British Journal of Anaesthesia·N DietisD G Lambert
Jun 6, 2008·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Richard D WainfordDaniel R Kapusta
Jul 22, 1997·Proceedings of the National Academy of Sciences of the United States of America·Y A KolesnikovG W Pasternak
Oct 22, 2011·Psychopharmacology·Maria MeringoloAldo Badiani
Mar 21, 2012·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Gavril W Pasternak
Oct 7, 2004·Neuropharmacology·Gavril W Pasternak
Sep 9, 2015·Frontiers in Physiology·Casey Y Carmichael, Richard D Wainford
Oct 31, 2015·British Journal of Pain·Sophy K Gretton, Joanne Droney
Oct 28, 2003·Synapse·Elizabeth A BolanGavril W Pasternak
Aug 4, 2018·Journal of Molecular Neuroscience : MN·Qiang Wu, Li Liu
May 24, 2006·Anesthesia and Analgesia·Eveline L A van DorpAlbert Dahan
Jun 14, 2005·Medicinal Research Reviews·Gavin J Kilpatrick, Terry W Smith
Jan 26, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Guobin BaoGang Pei

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.